129 related articles for article (PubMed ID: 8159008)
21. Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment.
Del Campo JM; Felip E; Rubio D; Vidal R; Bermejo B; Colomer R; Zanon V
Gynecol Oncol; 1994 Apr; 53(1):27-32. PubMed ID: 8175018
[TBL] [Abstract][Full Text] [Related]
22. Impact of second look laparotomy and secondary cytoreductive surgery at second-look laparotomy in ovarian cancer patients.
Obermair A; Sevelda P
Acta Obstet Gynecol Scand; 2001 May; 80(5):432-6. PubMed ID: 11328220
[TBL] [Abstract][Full Text] [Related]
23. A review of second-look laparotomy for ovarian cancer.
Cain JM; Saigo PE; Pierce VK; Clark DG; Jones WB; Smith DH; Hakes TB; Ochoa M; Lewis JL
Gynecol Oncol; 1986 Jan; 23(1):14-25. PubMed ID: 3943748
[TBL] [Abstract][Full Text] [Related]
24. Second-look laparotomy in the management of patients after radical surgery for ovarian cancer.
Tuxen MK; Lund B; Hansen OP; Hansen M
Ann Oncol; 1993 Feb; 4(2):169-71. PubMed ID: 8448085
[TBL] [Abstract][Full Text] [Related]
25. The prognostic and therapeutic value of second-look laparotomy in advanced ovarian cancer.
Bertelsen K; Hansen MK; Pedersen PH; Larsen G; Nyland M; Jacobsen M; Andersen JE
Br J Obstet Gynaecol; 1988 Dec; 95(12):1231-6. PubMed ID: 3224088
[TBL] [Abstract][Full Text] [Related]
26. Survival after second-look laparotomy in advanced ovarian epithelial cancer. Study of 86 patients.
de Gramont A; Drolet Y; Varette C; Louvet C; Gonzalez-Canall G; Krulik M; Cady J; Pigne A; Marpeau L; Barrat J
Eur J Cancer Clin Oncol; 1989 Mar; 25(3):451-7. PubMed ID: 2702999
[TBL] [Abstract][Full Text] [Related]
27. The changing role of "second-look" laparotomy in the management of epithelial carcinoma of the ovary.
Stuart GC; Jeffries M; Stuart JL; Anderson RJ
Am J Obstet Gynecol; 1982 Mar; 142(6 Pt 1):612-6. PubMed ID: 7199819
[TBL] [Abstract][Full Text] [Related]
28. Short-term effects of chemotherapy-surgery-chemotherapy regimen on clinically inoperable advanced ovarian cancer.
Feng Y; Sun T
Chin Med J (Engl); 1998 Aug; 111(8):722-5. PubMed ID: 11245027
[TBL] [Abstract][Full Text] [Related]
29. Abdominopelvic irradiation for stage II-IV ovarian carcinoma patients with limited or no residual disease at second-look laparotomy after completion of cisplatinum-based combination chemotherapy.
Menczer J; Modan M; Brenner J; Ben-Baruch G; Brenner H
Gynecol Oncol; 1986 Jun; 24(2):149-54. PubMed ID: 3710262
[TBL] [Abstract][Full Text] [Related]
30. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study.
Omura G; Blessing JA; Ehrlich CE; Miller A; Yordan E; Creasman WT; Homesley HD
Cancer; 1986 May; 57(9):1725-30. PubMed ID: 3513943
[TBL] [Abstract][Full Text] [Related]
31. Surgically documented response to intraperitoneal cisplatin, cytarabine, and bleomycin after intravenous cisplatin-based chemotherapy in advanced ovarian adenocarcinoma.
Piver MS; Lele SB; Marchetti DL; Baker TR; Emrich LJ; Hartman AB
J Clin Oncol; 1988 Nov; 6(11):1679-84. PubMed ID: 3183700
[TBL] [Abstract][Full Text] [Related]
32. Second-look surgery (SLO) in the management of carcinoma of the ovary.
Hernádi Z; Sápy T; Lukácskó L; Borsos A
Acta Chir Hung; 1997; 36(1-4):128-9. PubMed ID: 9408314
[TBL] [Abstract][Full Text] [Related]
33. The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma.
Le T; Adolph A; Krepart GV; Lotocki R; Heywood MS
Gynecol Oncol; 2002 May; 85(2):351-5. PubMed ID: 11972399
[TBL] [Abstract][Full Text] [Related]
34. Chemotherapy consisting of cisplatin, doxorubicin and cyclophosphamide as an adjunct to surgery in stage Ic-II epithelial ovarian carcinoma. Gynecologic Oncology Group of the Comprehensive Cancer Center Limburg.
De Pree N; Wils J
Anticancer Res; 1989; 9(6):1873-5. PubMed ID: 2697191
[TBL] [Abstract][Full Text] [Related]
35. Implications of second-look laparotomy in the context of optimally resected stage III ovarian cancer: a non-randomized comparison using an explanatory analysis: a Gynecologic Oncology Group study.
Greer BE; Bundy BN; Ozols RF; Fowler JM; Clarke-Pearson D; Burger RA; Mannel R; DeGeest K; Hartenbach EM; Baergen RN; Copeland LJ
Gynecol Oncol; 2005 Oct; 99(1):71-9. PubMed ID: 16039699
[TBL] [Abstract][Full Text] [Related]
36. Long-term survival of 106 stage III ovarian cancer patients with minimal residual disease after second-look laparotomy and consolidation radiotherapy.
Petit T; Velten M; d'Hombres A; Marchal C; Montbarbon X; Mornex F; Quetin P; Gérard JP; Romestaing P; Carrie C
Gynecol Oncol; 2007 Jan; 104(1):104-8. PubMed ID: 16987544
[TBL] [Abstract][Full Text] [Related]
37. A reassessment of the role of second-look laparotomy in advanced ovarian cancer.
Ho AG; Beller U; Speyer JL; Colombo N; Wernz J; Beckman EM
J Clin Oncol; 1987 Sep; 5(9):1316-21. PubMed ID: 3625253
[TBL] [Abstract][Full Text] [Related]
38. Cisplatin based combination chemotherapy in the treatment of stage III ovarian epithelial tumors of low malignant potential.
Yazigi R; Munoz AK; Sandstad J; Lifshitz S; Choi DJ
Eur J Gynaecol Oncol; 1991; 12(6):451-5. PubMed ID: 1809577
[TBL] [Abstract][Full Text] [Related]
39. Cisplatin and cyclophosphamide in early epithelial ovarian carcinoma.
Chiara S; Conte PF; Bruzzone M; Falcone A; Sertoli MR; Carnino F; Mossetti C; Iura R; Durando C; Guercio E
Chemioterapia; 1987 Oct; 6(5):380-3. PubMed ID: 3427698
[TBL] [Abstract][Full Text] [Related]
40. Second-look procedures in ovarian cancer patients receiving six vs. nine courses of platinum, adriamycin, cytoxan (PAC) chemotherapy: the SCPMG experience 1982-1985.
Watring W; Semrad N; Alaverdian V; Latino F; Pretorius G
Gynecol Oncol; 1989 Feb; 32(2):245-7. PubMed ID: 2910787
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
